Arecor Therapeutics (LON:AREC) Releases Earnings Results

Arecor Therapeutics (LON:AREC) issued its quarterly earnings data on Monday. The company reported GBX 2 earnings per share (EPS) for the quarter, Digital Look Earnings reports. The firm had revenue of GBX 171 million during the quarter. Arecor Therapeutics had a negative return on equity of 197.54% and a negative net margin of 160.13%.

Arecor Therapeutics Stock Up 6.1%

Shares of LON:AREC opened at GBX 70 on Tuesday. The company has a quick ratio of 6.24, a current ratio of 2.05 and a debt-to-equity ratio of 6.06. Arecor Therapeutics has a 52-week low of GBX 35.40 and a 52-week high of GBX 100. The stock’s fifty day simple moving average is GBX 71.42 and its 200-day simple moving average is GBX 76.15. The company has a market capitalization of £26.43 million, a P/E ratio of -3.04 and a beta of -0.18.

Arecor Therapeutics Company Profile

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.